{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:25:01Z","timestamp":1789709101130,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03448-5","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:04:08Z","timestamp":1770879848000},"page":"1521-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type\u00a02 Diabetes"],"prefix":"10.1007","volume":"43","author":[{"given":"Kristina S.","family":"Boye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn N.","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin S.","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Matza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"3448_CR1","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.2147\/DDDT.S140767","volume":"12","author":"KC Corado","year":"2018","unstructured":"Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naive HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018;12:3731\u201340.","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"3448_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0210-5705(20)30183-7","volume":"42","author":"E Monte-Boquet","year":"2019","unstructured":"Monte-Boquet E, Verdugo RM, Navarro H, Quer JC, Ventayol P. Importance of adherence to treatment with direct-acting antivirals in hepatitis\u00a0C. Gastroenterol Hepatol. 2019;42(Suppl 1):14\u20139.","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"3448_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/MOO.0b013e32835f8048","volume":"21","author":"WR Reisacher","year":"2013","unstructured":"Reisacher WR, Visaya JM. Patient adherence to allergy immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2013;21(3):256\u201362.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"3","key":"3448_CR4","first-page":"278","volume":"28","author":"S Bjedov","year":"2016","unstructured":"Bjedov S, Ciglar M, Malekovic H. Attitudes of Croatian patients with severe mental illness towards long-acting injectable antipsychotics. Psychiatr Danub. 2016;28(3):278\u201383.","journal-title":"Psychiatr Danub"},{"issue":"1","key":"3448_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048537","volume":"12","author":"J Foster","year":"2022","unstructured":"Foster J, Beasley R, Braithwaite I, et al. Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. BMJ Open. 2022;12(1):e048537.","journal-title":"BMJ Open"},{"issue":"3","key":"3448_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/dom.13902","volume":"22","author":"LS Matza","year":"2020","unstructured":"Matza LS, Boye KS, Stewart KD, et al. Assessing patient preference between the dulaglutide pen and the semaglutide pen: a crossover study (PREFER). Diabetes Obes Metab. 2020;22(3):355\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3448_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248471","volume":"16","author":"T De Backer","year":"2021","unstructured":"De Backer T, Van Nieuwenhuyse B, De Bacquer D. Antihypertensive treatment in a general uncontrolled hypertensive population in Belgium and Luxembourg in primary care: therapeutic inertia and treatment simplification. The SIMPLIFY study. PLoS ONE. 2021;16(4):e0248471.","journal-title":"PLoS ONE"},{"issue":"1","key":"3448_CR8","first-page":"53","volume":"82","author":"S Pegler","year":"2010","unstructured":"Pegler S, Underhill J. Evaluating the safety and effectiveness of new drugs. Am Fam Physician. 2010;82(1):53\u20137.","journal-title":"Am Fam Physician"},{"key":"3448_CR9","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.2147\/PPA.S268499","volume":"14","author":"MH Elnaem","year":"2020","unstructured":"Elnaem MH, Irwan NA, Abubakar U, et al. Impact of medication regimen simplification on medication adherence and clinical outcomes in patients with long-term medical conditions. Patient Prefer Adherence. 2020;14:2135\u201345.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3448_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/107602960100700108","volume":"7","author":"JA Hixson-Wallace","year":"2001","unstructured":"Hixson-Wallace JA, Dotson JB, Blakey SA. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost. 2001;7(1):33\u20137.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"3448_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/00126334-200407010-00007","volume":"36","author":"VE Stone","year":"2004","unstructured":"Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808\u201316.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"3448_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1176\/ps.2009.60.3.337","volume":"60","author":"PJ Raue","year":"2009","unstructured":"Raue PJ, Schulberg HC, Heo M, Klimstra S, Bruce ML. Patients\u2019 depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study. Psychiatr Serv. 2009;60(3):337\u201343.","journal-title":"Psychiatr Serv"},{"issue":"11","key":"3448_CR13","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1185\/03007995.2014.952715","volume":"30","author":"SL Shingler","year":"2014","unstructured":"Shingler SL, Bennett BM, Cramer JA, et al. Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin. 2014;30(11):2329\u201341.","journal-title":"Curr Med Res Opin"},{"key":"3448_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2147\/PPA.S90842","volume":"9","author":"HL Gelhorn","year":"2015","unstructured":"Gelhorn HL, Poon JL, Davies EW, et al. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type\u00a02 diabetes patients in the UK. Patient Prefer Adherence. 2015;9:1611\u201322.","journal-title":"Patient Prefer Adherence"},{"key":"3448_CR15","volume-title":"Prescribing information","author":"Mounjaro","year":"2022","unstructured":"Mounjaro. Prescribing information. Indianapolis: Eli Lilly and Company; 2022."},{"key":"3448_CR16","volume-title":"Prescribing information","author":"Ozempic","year":"2017","unstructured":"Ozempic. Prescribing information. Plainsboro: Novo Nordisk A\/S; 2017."},{"key":"3448_CR17","volume-title":"Instructions for use","author":"Trulicity","year":"2018","unstructured":"Trulicity. Instructions for use. Indianapolis: Eli Lilly and Company; 2018."},{"issue":"3","key":"3448_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type\u00a02 diabetes. Eur J Health Econ. 2011;12(3):219\u201330.","journal-title":"Eur J Health Econ"},{"issue":"7","key":"3448_CR19","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s11136-021-02808-2","volume":"30","author":"LS Matza","year":"2021","unstructured":"Matza LS, Cutts KN, Stewart KD, et al. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type\u00a02 diabetes. Qual Life Res. 2021;30(7):2033\u201343.","journal-title":"Qual Life Res"},{"key":"3448_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S187907","volume":"13","author":"VT Thieu","year":"2019","unstructured":"Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes. Patient Prefer Adherence. 2019;13:561\u201376.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3448_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000685","volume":"7","author":"AA Ayele","year":"2019","unstructured":"Ayele AA, Tegegn HG, Ayele TA, Ayalew MB. Medication regimen complexity and its impact on medication adherence and glycemic control among patients with type\u00a02 diabetes mellitus in an Ethiopian general hospital. BMJ Open Diabetes Res Care. 2019;7(1):e000685.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"3448_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychores.2013.11.003","volume":"76","author":"ST de Vries","year":"2014","unstructured":"de Vries ST, Keers JC, Visser R, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type\u00a02 diabetes. J Psychosom Res. 2014;76(2):134\u20138.","journal-title":"J Psychosom Res"},{"issue":"1","key":"3448_CR23","first-page":"23","volume":"57","author":"TS Abdelaziz","year":"2019","unstructured":"Abdelaziz TS, Sadek KM. Effect of reducing medication regimen complexity on glycaemic control in patients with diabetes. Rom J Intern Med. 2019;57(1):23\u20139.","journal-title":"Rom J Intern Med"},{"issue":"1","key":"3448_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s41687-023-00614-7","volume":"7","author":"KD Stewart","year":"2023","unstructured":"Stewart KD, Matza LS, Patel H, Boye KS. Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type\u00a02 diabetes. J Patient Rep Outcomes. 2023;7(1):89.","journal-title":"J Patient Rep Outcomes"},{"key":"3448_CR25","unstructured":"Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Silver Spring, MD (USA). 2025. www.fda.gov\/media\/159500\/download. Accessed 15 Aug 2025."},{"key":"3448_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-014-0176-2","volume":"12","author":"E Anthoine","year":"2014","unstructured":"Anthoine E, Moret L, Regnault A, Sebille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12:176.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"3448_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mpr.352","volume":"20","author":"A Rouquette","year":"2011","unstructured":"Rouquette A, Falissard B. Sample size requirements for the internal validation of psychiatric scales. Int J Methods Psychiatr Res. 2011;20(4):235\u201349.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"2","key":"3448_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1891\/jnum.10.2.135.52552","volume":"10","author":"KG Sapnas","year":"2002","unstructured":"Sapnas KG, Zeller RA. Minimizing sample size when using exploratory factor analysis for measurement. J Nurs Meas. 2002;10(2):135\u201354.","journal-title":"J Nurs Meas"},{"issue":"5","key":"3448_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1464-5491.1990.tb01421.x","volume":"7","author":"C Bradley","year":"1990","unstructured":"Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990;7(5):445\u201351.","journal-title":"Diabet Med"},{"key":"3448_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1477-7525-7-83","volume":"7","author":"M Brod","year":"2009","unstructured":"Brod M, Hammer M, Christensen T, Lessard S, Bushnell DM. Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes device). Health Qual Life Outcomes. 2009;7:83.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3448_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/001316446002000116","volume":"20","author":"HF Kaiser","year":"1960","unstructured":"Kaiser HF. The application of electronic computers to factor analysis. Educ Psychol Meas. 1960;20(1):141\u201351.","journal-title":"Educ Psychol Meas"},{"key":"3448_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/oso\/9780198527695.003.0003","volume-title":"Assessing quality of life in clinical trials: methods and practice","author":"RD Hays","year":"2005","unstructured":"Hays RD, Revicki D. Reliability and validity (including responsiveness). In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials: methods and practice. Oxford: Oxford University Press; 2005. p. 25\u201330."},{"key":"3448_CR33","volume-title":"Psychometric theory","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.","edition":"3rd ed"},{"issue":"2","key":"3448_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363.","journal-title":"J Chiropr Med"},{"key":"3448_CR35","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates; 1988."},{"issue":"6","key":"3448_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type\u00a02 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"3448_CR37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056\u201364.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"3448_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkab324","volume":"77","author":"P Thoueille","year":"2022","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290\u2013302.","journal-title":"J Antimicrob Chemother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03448-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:14:22Z","timestamp":1775726062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03448-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3448"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03448-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kristina Boye is employed by and owns shares in Eli Lilly and Company. Louis Matza, Katelyn Cutts, and Karin Coyne are employed by Thermo Fisher Scientific, which received funding from Lilly for the time spent conducting this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All study methods and materials, as well as all eight clinical sites participating in the study, were approved by an independent review board (Salus Institutional Review Board study number 23069). The study was performed according to the Helsinki Declaration of 1964 and its later amendments. Participants provided informed consent before completing any study measures and were remunerated for their time. The consent form informed participants that their data may be published, but they would not be personally identified in any publications.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}